Evicenter
P&T meetings

Relutrigine

SCN2A- and SCN8A-related developmental and epileptic encephalopathies

Regulatory submission
NDA submitted in early 2026
Launch
Not announced
Last updated
72 sources

Product information and disease descriptionProduct descriptionProduct information

Dosage forms and strengths

1 evidence topic · 1 source

Clinical product formulation: material safety data sheet

No evidence found.

Formulation strength

No evidence found.